Clinical Trial Update: Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluating Abraxane with or without Tigatuzumab in metastatic triple-negative breast cancer. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Tigatuzumab (tigatuzumab)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-09-13